Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-cash Items (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Non-cash Items for 14 consecutive years, with $88.6 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 53.47% to $88.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.6 million through Dec 2025, down 53.47% year-over-year, with the annual reading at $88.6 million for FY2025, 407.41% up from the prior year.
  • Non-cash Items for Q4 2025 was $88.6 million at Gyre Therapeutics, up from $15.1 million in the prior quarter.
  • The five-year high for Non-cash Items was $444.2 million in Q4 2023, with the low at $100000.0 in Q1 2024.
  • Average Non-cash Items over 5 years is $42.4 million, with a median of $7.4 million recorded in 2023.
  • The sharpest move saw Non-cash Items plummeted 98.65% in 2024, then soared 16118.52% in 2025.
  • Over 5 years, Non-cash Items stood at $3.9 million in 2021, then surged by 224.79% to $12.7 million in 2022, then soared by 3406.73% to $444.2 million in 2023, then tumbled by 57.14% to $190.4 million in 2024, then plummeted by 53.47% to $88.6 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $88.6 million, $15.1 million, and $15.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.